Should You Buy IO Biotech Inc (IOBT) Stock After it Is Higher By 39.39% in a Week?

IO Biotech Inc (IOBT) stock has gained 39.39% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

IO Biotech Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on IOBT!

See Full IOBT Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With IOBT Stock Today?

IO Biotech Inc (IOBT) stock is higher by 17.36% while the S&P 500 is down -0.08% as of 12:41 PM on Monday, Nov 27. IOBT has risen $0.20 from the previous closing price of $1.18 on volume of 339,740 shares. Over the past year the S&P 500 has gained 14.93% while IOBT is down -55.48%. IOBT lost -$2.46 per share in the over the last 12 months. To screen for more stocks like IO Biotech Inc click here.

More About IO Biotech Inc

IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Click Here to get the full Stock Report for IO Biotech Inc stock.